Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
GLP-1 indirectly benefits cardiovascular disease (CVD) by addressing risk factors like hypertension, dyslipidemia, and obesity that are aggravated in diabetes
Ohio to end GLP-1 drug weight loss coverage for state workers COLUMBUS, Ohio (WSYX) The Ohio Department of Administrative Services announced that coverage for GLP-1 drugs for weight loss, including Ozempic and Mounjaro, will end for state employees on July 1, 2025
After 28 weeks, the results showed people in each of the treatment groups lost on average: 20 pounds (lb) with a combination treatment of 15 milligrams (mg) phentermine with 92 mg topiramate 13.6 lb with 15 mg phentermine only 14.7 lb for 92 mg topiramate only This suggests that taking the drugs together rather than separately may result in greater weight loss
Sticking to the same day each week helps regulate the medications effects and supports steady blood glucose or weight management
BY INDICATION The diabetes indication segment accounted for the largest share of the market
Many patients find that outdoor trips become more enjoyable as treatment progresses and physical capacity improves
